AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02291731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous use of topical autologous serum
Description: Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
Study NCT05304169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate (Eligard® 45 mg).
Description: Semiannually Leuprorelin Acetate (Eligard® 45 mg).
Study NCT01440491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy exercise
Description: once a day, during 15 minutes, for 12 weeks
Study NCT00910442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione precursors
Description: HIV+ patients were assigned to 7 day diets containing either NAC or Gln
Study NCT00910442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione precursors
Description: HIV+ patients were assigned to 7 day diets containing either NAC or Gln
Study NCT02219022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study NCT02993146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02993146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02993146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Given PO
Study NCT02993146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT02516514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia
Description: Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
Study NCT02516514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia
Description: Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
Study NCT02219022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Study NCT02219022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Study NCT00892151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLUCOFACTS® Deluxe
Description: Diabetes Data Management Software
Study NCT03748173 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized Infasurf
Description: Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
Study NCT00743067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
Study NCT02915900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropin removal test
Description: Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
Study NCT02915900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine IVF method
Description: Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
Study NCT06577038 — intervention group
Intervention type: DEVICE
Intervention: PCI with use of IVL
Description: Use of IVL for the treatment of calcific coronary artery lesions at operator's discretion
Study NCT00527293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
Study NCT00527293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 3-dimensional conformal radiotherapy twice daily for 5-10 days.
Study NCT00527293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
Study NCT01558440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: A diet that is being fed to the young infants.
Study NCT01558440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: F-100
Description: • F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
Study NCT01558440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diluted F-100
Description: 300 ml of water is added to 1000 ml of f-100
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)
Study NCT00316082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2000 mg, as needed (12 months LT)
Study NCT04169308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L® Filler injection
Description: Restylane-L® Filler injection into the soft tissue of the nose
Study NCT05361226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy measurement
Description: Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters.
Study NCT05361226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accuracy measurement
Description: Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters.
Study NCT04605796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with Bevacizumab
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
Study NCT03549650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan Polysulfate Na 100Mg Cap
Description: Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.
Study NCT03549650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.
Study NCT01655290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)
Description: Other (Diagnostic)
Study NCT00561210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crucial
Description: Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Study NCT00561210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sondalis HP
Description: Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Study NCT01509222 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized nutrition counseling
Study NCT00587964 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY.
Study NCT01696201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study NCT02870140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRAFLEX
Description: Percutaneous Coronary Intervention
Study NCT04571242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTM Programming
Description: DTM-SCS programming
Study NCT02870140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Percutaneous Coronary Intervention
Study NCT01429480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block
Study NCT01429480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Ultrasound Guided Posterior TAP Block
Study NCT01429480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Study NCT04209075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biomebliss
Description: BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
Study NCT04209075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
Study NCT04209075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator
Study NCT01758354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pompe disease newborn screening
Description: DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
Study NCT01696487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High oral Fructose challenge (150g per day for 28 days)
Study NCT05140928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dadiah Pudding
Description: Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
Study NCT05140928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pudding without Dadiah
Description: Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
Study NCT03260166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
Study NCT04571242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SCS programming
Description: Conventional SCS programming
Study NCT01994603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-in or Opt-out testing
Description: Study participants will be offered a health screening onsite.
Study NCT01994603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Study participants will be invited to participate in a focus group discussion.
Study NCT02475122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: azygos blood flow measurements by MRI
Study NCT01939548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
Study NCT01939548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID until the Week 12 visit
Study NCT01939548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
Study NCT01278134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus placebo
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study NCT02519426 — intervention group
Intervention type: PROCEDURE
Intervention: Mandibular third molar surgery
Description: Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
Study NCT00641602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg once daily
Study NCT00641602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg once daily
Study NCT04532931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (Paracetamol)
Description: SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
Study NCT04532931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
Study NCT04532931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Description: SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
Study NCT04532931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir plus Nitazoxanide
Description: SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
Study NCT04532931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir
Description: SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days
Study NCT01522378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123 iodine metaiodobenzylguanidine
Description: 10 millicurie (mCi) (370 MBq)
Study NCT03824795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MGB-BP-3
Description: MGB-BP-3
Study NCT01135381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR-Enhanced Care
Description: Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
Study NCT01408316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
Study NCT03468114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Start
Description: Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
Study NCT03468114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participant households will receive 4 visits by health extension workers delivering standard care
Study NCT02533050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
Study NCT03443362 — intervention group
Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
Study NCT03443362 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling
Study NCT01129440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
Study NCT01129440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.